EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.
作者信息
Bijlsma Johannes Wj
机构信息
Rheumatology, UMCUtrecht, Utrecht, The Netherlands
出版信息
Ann Rheum Dis. 2021 Apr;80(4):411-412. doi: 10.1136/annrheumdis-2020-219773. Epub 2021 Feb 9.
Abstract
摘要
相似文献
1
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.欧洲抗风湿病联盟2020年12月关于风湿病患者接种新型冠状病毒疫苗的观点
Ann Rheum Dis. 2021 Apr;80(4):411-412. doi: 10.1136/annrheumdis-2020-219773. Epub 2021 Feb 9.
2
EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients' questions.欧洲抗风湿联盟（EULAR）2021年关于风湿性和肌肉骨骼疾病（RMDs）患者接种新型冠状病毒疫苗（SARS-CoV-2）的最新观点：回答患者问题的指南
Ann Rheum Dis. 2022 Jun;81(6):786-788. doi: 10.1136/annrheumdis-2021-221965. Epub 2022 Feb 4.
3
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'.关于“欧洲抗风湿病联盟（EULAR）2020年12月对风湿性疾病（RMDs）患者接种新型冠状病毒肺炎（SARS-CoV-2）疫苗的观点”的通信
Ann Rheum Dis. 2021 Oct;80(10):e156. doi: 10.1136/annrheumdis-2021-220541. Epub 2021 Apr 27.
4
Response to: 'Correspondence on 'EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs'' by Bugatti .对布加迪所著的《关于“2020年12月欧洲抗风湿病联盟对类风湿性疾病患者接种SARS-CoV-2疫苗的观点”的通信》的回复
Ann Rheum Dis. 2021 Oct;80(10):e157. doi: 10.1136/annrheumdis-2021-220564. Epub 2021 Apr 27.
5
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.接种 SARS-CoV-2 疫苗在风湿免疫疾病患者中的安全性：来自 EULAR 冠状病毒疫苗（COVAX）医生报告登记处的结果。
Ann Rheum Dis. 2022 May;81(5):695-709. doi: 10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.
6
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.风湿与肌肉骨骼疾病患者感染 SARS-CoV-2 及接种 SARS-CoV-2 疫苗的风险和预后：一项系统文献综述，旨在为 EULAR 建议提供信息。
Ann Rheum Dis. 2022 Mar;81(3):422-432. doi: 10.1136/annrheumdis-2021-221575. Epub 2021 Dec 7.
7
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.欧洲抗风湿病联盟关于2019冠状病毒病背景下风湿性和肌肉骨骼疾病患者管理及疫苗接种的建议：2021年11月更新版
Ann Rheum Dis. 2022 Dec;81(12):1628-1639. doi: 10.1136/annrheumdis-2021-222006. Epub 2022 Feb 23.
8
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry.SARS-CoV-2 疫苗在青少年炎症性风湿和肌肉骨骼疾病患者和青少年特发性关节炎成人患者中的安全性：来自 EULAR COVAX 医生报告登记处的数据。
RMD Open. 2022 Jul;8(2). doi: 10.1136/rmdopen-2022-002322.
9
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.五种不同的新型冠状病毒2疫苗在病情缓解或疾病活动度低的自身免疫性风湿和肌肉骨骼疾病患者及健康对照中的体液和细胞免疫原性及安全性：一项单中心研究
Front Immunol. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248. eCollection 2022.
10
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.与炎症性风湿和肌肉骨骼疾病患者接种 SARS-CoV-2 疫苗后疾病发作相关的因素：来自医生报告的 EULAR 冠状病毒疫苗（COVAX）登记处的结果。
Ann Rheum Dis. 2024 Oct 21;83(11):1584-1595. doi: 10.1136/ard-2024-225869.
引用本文的文献
1
Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study.包括加强剂量的SARS-CoV-2疫苗接种方案在系统性红斑狼疮患者中的免疫原性：一项前瞻性多中心研究的数据
Vaccines (Basel). 2025 Jan 27;13(2):127. doi: 10.3390/vaccines13020127.
2
Clinical characteristics and outcomes of COVID-19 in pediatric patients with rheumatic diseases.风湿性疾病患儿新冠病毒病（COVID-19）的临床特征及预后
Pediatr Res. 2024 Oct 7. doi: 10.1038/s41390-024-03561-1.
3
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.与炎症性风湿和肌肉骨骼疾病患者接种 SARS-CoV-2 疫苗后疾病发作相关的因素：来自医生报告的 EULAR 冠状病毒疫苗（COVAX）登记处的结果。
Ann Rheum Dis. 2024 Oct 21;83(11):1584-1595. doi: 10.1136/ard-2024-225869.
4
Attitudes toward COVID-19 Vaccination: A Survey of Chinese Patients with Rheumatic Diseases.对新冠病毒疫苗接种的态度：一项针对中国风湿病患者的调查
Vaccines (Basel). 2022 Sep 23;10(10):1604. doi: 10.3390/vaccines10101604.
5
Systemic sclerosis in the time of COVID-19.新冠疫情时期的系统性硬化症
Lancet Rheumatol. 2022 Aug;4(8):e566-e575. doi: 10.1016/S2665-9913(22)00130-8. Epub 2022 Jul 21.
6
Recommendations on SARS-CoV-2 vaccination in adult patients with rheumatic diseases.关于风湿性疾病成年患者接种新型冠状病毒2疫苗的建议。
Rheumatol Immunol Res. 2021 Dec 31;2(4):213-216. doi: 10.2478/rir-2021-0029. eCollection 2021 Dec 1.
7
Self-Reported COVID-19 Vaccines' Side Effects among Patients Treated with Biological Therapies in Saudi Arabia: A Multicenter Cross-Sectional Study.沙特阿拉伯接受生物疗法治疗的患者自我报告的新冠疫苗副作用：一项多中心横断面研究
Vaccines (Basel). 2022 Jun 20;10(6):977. doi: 10.3390/vaccines10060977.
8
COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis.脊柱关节炎患者的 COVID-19 结局与疫苗接种
Rheumatol Ther. 2022 Aug;9(4):993-1016. doi: 10.1007/s40744-022-00462-9. Epub 2022 May 22.
9
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus.新冠病毒灭活疫苗和mRNA疫苗在系统性红斑狼疮患者中的免疫原性和安全性
Ther Adv Musculoskelet Dis. 2022 Apr 19;14:1759720X221089586. doi: 10.1177/1759720X221089586. eCollection 2022.
10
Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis.关注性别：类风湿关节炎管理中我们需要了解的内容。
J Pers Med. 2022 Mar 20;12(3):499. doi: 10.3390/jpm12030499.
Zotero 插件